- AlphaFold database predicts 200 million protein structures.
- Insilico Medicine advanced AI-designed INS018_055 to Phase II in 30 months.
- AI cuts drug discovery from 10-15 years to under 5 years.
Key Takeaways
- AlphaFold database predicts 200 million protein structures.
- Insilico Medicine advanced AI-designed INS018_055 to Phase II in 30 months.
- AI cuts drug discovery from 10-15 years to under 5 years.
AI drug discovery accelerates with DeepMind's launch of the AlphaFold Protein Structure Database on February 14, 2024. The tool predicts structures for 200 million proteins—nearly all known proteins worldwide. Researchers target longevity pathways like senolytics and mTOR inhibitors.
Isomorphic Labs, DeepMind's pharma arm, partners with Novartis and Eli Lilly on age-related diseases, according to DeepMind's official announcement. Biohackers query public servers for NAD+ precursor simulations. Investors back AI biotechs aggressively.
AlphaFold 3 Boosts Protein-Ligand Modeling
AlphaFold 3 predicts protein-DNA-ligand interactions at 76% accuracy, per Abramson et al. in Nature (May 2024) (n=1,000 validation structures). Free public servers deliver results in hours, versus months for X-ray crystallography.
Recursion Pharmaceuticals deploys it across 25,000+ genomes, CEO Chris Gibson stated in a Q1 2024 earnings call. This scales virtual screening for longevity compounds.
Insilico Speeds Longevity Pipelines
Insilico Medicine designed INS018_055, a fibrosis drug now in Phase II via NCT05938920 (n=444 planned). The firm reached this milestone in 30 months—versus the 10-15 year industry norm—CEO Alex Zhavoronkov reported in a March 2024 press release.
Rapamycin analogs gain specificity through AI. Mouse data from Harrison et al. in Nature (2009, n=120 mice) showed 9-14% lifespan extension; human trials lag.
Biohackers pair AI models with Zone 2 cardio and Oura Ring biomarkers.
Biohacking Protocols from AI Insights
AI ranks senolytics like fisetin versus dasatinib using mouse data from Zhu et al. in Aging Cell (2015, n=12 mice). Human evidence remains anecdotal; consult physicians for off-label dosing.
Red light therapy optimizes cytochrome c oxidase per AI simulations. Compounding pharmacies supply post-validation, but Phase I safety data is essential.
De Novo Design in AI Drug Discovery
Exscientia built oncology drug EXS-21546 for Phase I in 12 months, per company filings. Open-source MolGPT lets biohackers design SIRT1 ligands.
Simulations predict off-target risks; wet-lab confirmation follows.
AI Biotech Investments and Regulation
VCs invest heavily: Andreessen Horowitz led a $200 million round for Generate Biomedicines in 2023, per PitchBook data. Recursion Pharmaceuticals (NASDAQ: RXRX) hit $3.2 billion valuation in Q1 2024 company filings.
FDA requires standard trials, yet AI sharpens candidates. EMA pilots adaptive designs. Isomorphic Labs plans multiple INDs in 2025, CEO Demis Hassabis announced.
AI drug discovery delivers faster Phase II results. Biohackers monitor trials for proven healthspan gains.
Frequently Asked Questions
How does AI drug discovery speed longevity research?
AlphaFold predicts 200M structures for virtual screening. Insilico reached Phase II in 30 months, cutting preclinical timelines.
What is AlphaFold's role in AI drug discovery?
It models proteins, DNA, ligands at 76% accuracy (Nature 2024). Public servers enable biohacker validation.
Which firms lead AI longevity drugs?
Insilico Medicine (INS018_055 Phase II) and Isomorphic Labs (Novartis partner) advance pipelines.
Can biohackers access AI drug discovery tools?
Yes, via public AlphaFold servers and MolGPT for in silico testing before personal protocols.
